2025
Monitoring Inflammatory Bowel Disease Activity: When, How and Why.
Gaidos J, Hashash J. Monitoring Inflammatory Bowel Disease Activity: When, How and Why. The American Journal Of Gastroenterology 2025 PMID: 40488637, DOI: 10.14309/ajg.0000000000003582.Peer-Reviewed Original ResearchInflammatory bowel diseaseActive intestinal inflammationIntestinal inflammationIBD careInflammatory bowel disease managementControl of inflammationMeasures of inflammationLack of symptomsPresence of symptomsTime of evaluationClinical remissionDisease remissionDisease activityClinical endpointsClinical symptomsTreatment endpointRadiographic assessmentCrohn's diseaseIntestinal ultrasoundBiochemical markersUlcerative colitisBowel disease
2016
RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER
Otto MW, Pollack MH, Dowd SM, Hofmann SG, Pearlson G, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER. Depression And Anxiety 2016, 33: 737-745. PMID: 27315514, PMCID: PMC5958622, DOI: 10.1002/da.22531.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBenzodiazepine usePanic disorderDCS augmentationMulticenter trialD-cycloserineRecent multicenter trialPanic Disorder Severity ScaleExposure-based cognitive-behavioral therapySessions of treatmentStudy pillsPrimary outcomeRandomized trialsBaseline severityPrimary diagnosisAugmentation effectTreatment responseTreatment endpointBooster sessionsSeverity ScaleRole of severityBehavioral therapyDCS efficacyBeneficial effectsPilot study
2015
Clobetasol's Influence on the Management and Cost of Skin Overgrowth Associated with the Bone-Anchored Hearing Aid.
Hildrew DM, Guittard JA, Carter JM, Molony TB. Clobetasol's Influence on the Management and Cost of Skin Overgrowth Associated with the Bone-Anchored Hearing Aid. Ochsner Journal 2015, 15: 277-83. PMID: 26413004, PMCID: PMC4569164.Peer-Reviewed Original ResearchBone-anchored hearing aidsSoft tissue overgrowthTraditional treatment groupClobetasol creamTreatment groupsTriamcinolone injectionSkin reactionsGranulation tissueBone-anchored hearing aidEarly postoperative careTopical clobetasol creamTraditional treatment regimenFirst objective comparisonHearing aidsCompliant patientsPostoperative careSurgical revisionTreatment regimenPostoperative proceduresOffice treatmentRevision surgeryPatient outcomesTreatment outcomesTreatment endpointPatients
2014
Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder
Anagnostou E, Jones N, Huerta M, Halladay A, Wang P, Scahill L, Horrigan J, Kasari C, Lord C, Choi D, Sullivan K, Dawson G. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism 2014, 19: 622-636. PMID: 25096930, DOI: 10.1177/1362361314542955.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSpectrum disorderSymptom domainsEarly indicator of autism spectrum disorderMeasures of social communicationSocial communicationIndicator of autism spectrum disorderSocial communication impairmentsSocial communication measuresSocial communication deficitsSocial communication behaviorsCore deficitCommunication deficitsCommunication impairmentsAutism SpeaksPsychometric propertiesOutcome measuresAutismCommunication measuresTreatment targetCommunication behaviorsTreatment approachesDisordersMonthly conference callsTreatment endpoint
1999
Refractory disease, new horizons and patient–physician relationships
Glode L, Petrylak D. Refractory disease, new horizons and patient–physician relationships. Prostate Cancer And Prostatic Diseases 1999, 2: 19-20. PMID: 12496852, DOI: 10.1038/sj.pcan.4500272.Peer-Reviewed Original ResearchMore cost-effective careRole of chemotherapyDisease-free intervalPhase III trialsUse of PSACost-effective careProstate cancer cellsPatient-physician relationshipAdvanced diseasePain controlIII trialsRefractory diseaseNumerous new targetsFree intervalProstate cancerTreatment endpointSurrogate endpointsBiologic understandingCancer cellsDisease targetsEndpointNew targetsGrowth factor interactionsChemotherapyDisease
1996
Behavioral Therapy in Children and Adolescents with Obsessive-Compulsive Disorder: A Pilot Study
Scahill L, Vitulano L, Brenner E, Lynch K, King R. Behavioral Therapy in Children and Adolescents with Obsessive-Compulsive Disorder: A Pilot Study. Journal Of Child And Adolescent Psychopharmacology 1996, 6: 191-202. PMID: 9231312, DOI: 10.1089/cap.1996.6.191.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleBehavioral treatmentBehavioral therapyRandomized clinical trialsTreatment of childrenChildren's Yale-Brown Obsessive Compulsive ScaleBehavioral therapy programObsessive Compulsive ScaleMedication treatmentPrimary diagnosisMonths posttreatmentClinical trialsTreatment endpointBooster sessionsDose reductionDose requirementsMedicationsUseful adjunctTherapeutic gainTreatment programTherapy programPilot studyCompulsive ScaleTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply